Research Beam added a report on “EpiCast Report: Hodgkins Lymphoma - Epidemiology Forecast to 2024” Enquiry about report: http://www.researchbeam.com/epicast-report-hodgkins-lymphoma-epidemiology-forecast-to-2024-market/enquire-about-report

1. EpiCast Report: Hodgkins
Lymphoma - Epidemiology
Forecast to 2024
TELEPHONE: +1 (503) 894-6022
E-MAIL: sales@researchbeam.com

2. Report Overview
Hodgkins lymphoma (HL), also known as Hodgkins disease, is a type of lymphoma, a cancerous condition
that affects the lymphatic system and occurs in both children and adults. HL is a rare disease that starts
with abnormal growth of the white blood cells, called lymphocytes, which spreads beyond the lymphatic
system and impairs the bodys immune system.
According to the American Cancer Society (ACS), HL can start anywhere in the lymphoid tissue of body,
but quite often starts in the upper part of body with main sites in the neck, the chest, or under the arms.
HL mostly spreads through lymph vessels to other lymph nodes, and in advanced stages can even invade
the bloodstream and spread to other organs including the liver, lungs, and bone marrow. The most
common symptoms of HL include enlarged lymph nodes under the skin of the neck, under the arm, or in
the groin, fever (which can come and go over several days or weeks) without an infection; drenching night
sweats, and weight loss.
To forecast the diagnosed incident cases and five-year diagnosed prevalent cases of HL in 7MM,
Epidemiologists obtained data from population-based studies that provided country-specific data in each
of the 7MM. In addition, epidemiologists used the staging system for HL known as the Cotswold system,
which is a modification of the older Ann Arbor system, to segment the diagnosed incident cases of HL in
the 7MM into stages I, II, III, and IV.
Read More At : http://www.researchbeam.com/epicast-report-hodgkins-lymphoma-epidemiology-
forecast-to-2024-market

3. Report Overview
Scope
The Hodgkins Lymphoma (HL) EpiCast Report provides an overview of the risk factors and global trends of
HL in the 7MM (US, France, Germany, Italy, Spain, UK and Japan). It includes a 10-year epidemiology
forecast for the diagnosed incident cases of HL, segmented by age, sex, and clinical stage at diagnosis, and
types (classical HL and nodular lymphocyte predominant HL, with classical HL further segmented into
subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted) in these
markets. In addition, epidemiologists provide a 10-year epidemiological forecast for the five-year
diagnosed prevalent cases of HL, as well as the number of HL diagnosed incident cases refractory to
chemoand radiation therapy, the number of HL diagnosed incident cases who received autologous stem
cell transplantation (ASCT), and HL diagnosed incident cases refractory to ASCT from 2014-2024 in these
markets.
The HL epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of
disease trends in the 7MM.

4. Table of Content
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Epidemiology 11
3.1 Disease Background 11
3.2 Risk Factors and Comorbidities 12
4 Appendix 44
4.1 Bibliography 44
4.2 About the Authors 47
Enquire At : http://www.researchbeam.com/epicast-report-hodgkins-lymphoma-epidemiology-
forecast-to-2024-market/enquire-about-report

5. FOR MORE DETAILS
Visit us at :
Stay With Us:
http://www.researchbeam.com/epicast-report-hodgkins-lymphoma-epidemiology-forecast-to-
2024-market
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
TELEPHONE: +1 (800) 910-6452
DIRECT: +1 (503) 894-6022
E-MAIL: sales@researchbeam.com